natgillin/translations-raw huggingface dataset:
Approximately 35% of the 579 patients aged 4 years and over who received treatment with sapropterin dihydrochloride (5 to 20 mg/kg/day) in the clinical trials for Kuvan experienced adverse reactions.
Približne u 35% z 579 pacientov vo veku 4 rokov a viac, ktorí boli liečení dihydrochloridom sapropterínu (5 až 20 mg/kg/deň) v klinických štúdiách s Kuvanom, sa vyskytli nežiaduce reakcie.
Approximately 350 patients were randomised into each of the 4 trial arms in the Part II of the trial.
V časti II skúšania bolo do každej zo 4 liečebných skupín randomizovaných približne 350 pacientov.
Approximately 37% of patients in clinical trials in type 1 Gaucher disease, and 58% of patients in a clinical trial in Niemann-Pick type C disease reported tremor on treatment.
V klinických štúdiách udávalo počas liečby približne 37 % pacientov s Gaucherovou chorobou typu 1 a približne 58 % pacientov s Niemannovou-Pickovou chorobou typu C trasenie .
Approximately 38% of the treated patients with a stoma (an artificial opening at the front of the abdomen to collect faeces or urine from the body) experienced stoma complications such as swelling of the stoma.
U približne 38 % liečených pacientov so stómiou (umelo vytvorený otvor v prednej časti brucha na odvádzanie stolice a moču z tela) sa objavili komplikácie stómie, ako napr. opuch stómie.
Approximately 38% of the treated patients with a stoma experienced gastrointestinal stoma complications.
U približne 38 % liečených pacientov so stómiou sa objavili gastrointestinálne komplikácie stómie.
Approximately 4 % of patients discontinued due to any adverse event in the 12-month study.
Približne 4 % pacientov prerušili liečbu v dôsledku nežiaducich účinkov počas 12-mesačnej štúdie.
Approximately 4-19% of the administered dose was excreted as unchanged riociguat via the kidneys.
Približne 4-19 % z podanej dávky sa vylúčilo ako nezmenený riociguát prostredníctvom obličiek.
Approximately 4.5% of patients can be expected to experience adverse reactions associated with the use of OPATANOL; however, only 1.6% of patients discontinued from the clinical studies due to these adverse reactions.
Dá sa očakávať, že približne 4,5% pacientov môže mať skúsenosť s nežiaducimi reakciami; avšak len 1,6% pacientov prerušilo klinické štúdie z dôvodu týchto nežiaducich reakcií v súvislosti s OPATANOLOM.
Approximately 40% and 17% of patients had mild (creatinine clearance ≥50 to <80 ml/min) or moderate (creatinine clearance ≥30 to <50 ml/min) renal impairment, respectively.
Približne 40 % pacientov malo miernu (klírens kreatinínu ≥ 50 až < 80 ml/min) a 17 % pacientov malo stredne závažnú (klírens kreatinínu ≥ 30 až < 50 ml/min) poruchu funkcie obličiek.
Approximately 40% of patients (in each of the treatment groups) received GPIIb/IIIa inhibitors in support of PCI (no information available regarding the type of GP IIb/IIIa inhibitor used).
Približne 40 % pacientov (v každej liečebnej skupine) užívalo inhibítory GP IIb/IIIa na podporu PCI (nie sú k dispozícii žiadne informácie o použitom type inhibítora GP IIb/IIIa).
Approximately 40% of patients had total lymphocyte counts reaching the lower limit of normal (LLN) by 6 months after each treatment course, and approximately 80% of patients had total lymphocyte counts reaching the LLN by 12 months after each course.
U približne 40 % pacientov celkový počet lymfocytov dosiahol dolnú hranicu normálu (Lower limit of normal, LNN) do 6 mesiacov po každom cykle liečby a u približne 80 % pacientov celkový počet lymfocytov dosiahol LLN do 12 mesiacov po každom cykle.
Approximately 40% of patients in study UC-II had failed prior anti-TNF treatment with infliximab.
Približne u 40 % pacientov v štúdii UC-II zlyhala predtým liečba antagonistom TNF infliximabom.
Approximately 40% of the administered product is excreted unchanged via the kidneys.
Asi 40% podaného lieku sa vylučuje obličkami v nezmenenej forme.
Approximately 40% of the total radioactivity was recovered in faeces and M1 and M2 (predominant) accounted for about 70% of that recovered in faeces.
Približne 40% celkovej rádioaktivity sa zistilo v stolici a M1 a M2 (prevládajúci) predstavovali približne 70% rádioaktivity zistenej v stolici.
Approximately 40% of treated subjects experienced systemic adverse reactions and approximately 54% experienced injection site reactions.
U približne 40 % liečených účastníkov štúdií sa prejavili systémové nežiaduce reakcie a u približne 54 % sa prejavili reakcie na mieste vpichu.
Approximately 40-50 hours after PhotoBarr administration, light should be delivered by a fibre optic diffuser passed through the central channel of a centring balloon.
Približne 40-50 hodín po podaní PhotoBarr sa má priviesť svetlo difuzérom z optických vlákien vedené cez centrálny kanál vystreďovacieho balónika.
Approximately 40-50 hours after PhotoBarr administration, light should be delivered by a fibre optic diffuser passed through the central channel of a centring balloon.
Približne 40-50 hodín po podaní PhotoBarru sa má priviesť svetlo difuzérom z optických vlákien vedené cez centrálny kanál vystreďovacieho balónika.
Approximately 41% of patients had severe COPD.
Asi 41 % pacientov malo ťažkú CHOCHP.
Approximately 42% of the dose is recovered in the urine over 7 days following a single 600 mg oral dose of telbivudine.
Po jednorazovej perorálnej dávke 600 mg telbivudínu sa počas 7 dní nájde v moči asi 42 % dávky.
Approximately 44% of an oral dose is recovered in the urine over 24 hours, with only 3.6% of the dose excreted as parent drug substance.
Približne 44% orálnej dávky sa vylúči močom v priebehu 24 hodín, len asi 3,6% dávky sa vylúči vo forme pôvodného liečiva.
Approximately 45% of patients had measurable soft tissue disease at study entry, and 12% of patients had visceral (lung and/or liver) metastases.
Približne 45 % pacientov malo merateľné ochorenie mäkkých tkanív pri vstupe do klinického skúšania a 12 % pacientov malo viscerálne (pľúcne a/alebo pečeňové) metastázy.
Approximately 45% of the active substance within the patch is released to the skin in 24 hours.
Za 24 hodín sa uvoľní do pokožky približne 45 % liečiva v náplasti.
Approximately 48% of the patients had failed 1 prior anti-TNF therapy and 52% had failed 2 or 3 prior anti-TNFα therapies.
Približne 48 % pacientov zlyhalo na 1 predchádzajúcej anti-TNF terapii a 52 % zlyhalo na 2 alebo 3 predchádzajúcich anti-TNFα terapiách.
approximately 48-fold.
Lopinavir:
approximately 48-fold.
↑ približne 48-násobne
Approximately 5 ml of water and 4 ml of air should be drawn into the syringe.
Do striekačky sa natiahne približne 5 ml vody a 4 ml vzduchu.
Approximately 5% of patients can be expected to experience adverse reactions .
Približne u 5 % pacientov sa môžu vyskytnúť nežiaduce reakcie.
Approximately 5% of patients can be expected to experience adverse reactions.
Približne u 5 % pacientov sa môžu vyskytnúť nežiaduce reakcie.
Approximately 5% of the SPRYCEL-treated patients who had normal baseline levels experienced grade 3 or 4 transient hypocalcaemia at some time during the course of the study.
Približne u 5 % pacientov liečených SPRYCELOM, ktorí mali normálne východiskové hladiny vápnika 3. alebo 4. stupňa, vznikla v určitom čase počas štúdie prechodná hypokalciémia.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Približne 50 % aplikovanej dávky je vylučované močom a zvyšok výkalmi.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Približne 50 % aplikovanej dávky je vylučovaných močom a zvyšok trusom .
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Približne 50 % aplikovanej dávky je vylučovaných močom a zvyšok výkalmi.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Približne 50 % aplikovanej dávky sa vylúči močom a zvyšok trusom.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Približne 50 % aplikovanej dávky sa vylúči močom a zvyšok výkalmi.
Approximately 50 % of the administered dose is eliminated via urine and the remainder via faeces.
Približne 50% aplikovanej dávky je vylučovaných močom a zvyšok výkalmi.
Approximately 50 % of the animals treated with the unformulated active substance showed erythema after challenging the induced animals.
Približne u 50 % indukovaných zvierat, liečených liečivom, sa objavil erytém.
Approximately 50 known or suspected cyanide victims aged 65 or older received hydroxocobalamin in clinical studies.
Približne 50 obetiam so známou otravou kyanidom alebo s podozrením na otravu kyanidom vo veku 65 rokov a starších bol podaný hydroxokobalamín v klinických štúdiách.
Approximately 50 ml of water to prepare the suspension
Približne 50 ml vody na prípravu suspenzie
Approximately 50% of constipation events occurred within the first 2 weeks of treatment.
K približne 50 % prípadov zápchy došlo v priebehu prvých 2 týždňov liečby.
Approximately 50% of methotrexate is bound to serum proteins.
Približne 50 % metotrexátu sa viaže na sérové proteíny.
Approximately 50% of patients treated with dexmedetomidine did not require rescue addition of midazolam during a median treatment period of 20.3 hours, not exceeding 24 hours.
Približne 50 % pacientov liečených dexmedetomidínom nepotrebovala pridanie záchranného sedatíva midazolam počas liečby so strednou hodnotou trvania 20,3 hodín, neprekračujúc 24 hodín.
Approximately 50% of patients were in functional Class III.
Približne 50 % pacientov bolo vo funkčnej triede III.
Approximately 50% of the administered dose is eliminated via urine and the remainder via faeces.
Približne 50 % aplikovanej dávky je vylučovaných močom a zvyšok výkalmi.
Approximately 50% of the total dose administered is rapidly absorbed transmucosally and becomes systemically available.
Približne 50% podanej dávky sa rýchle vstrebáva cez sliznicu a stáva sa systémovo dostupným.
Approximately 50-60% of an oral dose is excreted in the urine with the remainder eliminated in the faeces.
Približne 50 - 60 % perorálnej dávky sa vylučuje močom, zvyšok stolicou.
Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
Močom sa vylúčilo približne 51 % vo forme celkového topotekánu a 3 % sa vylúčili vo forme N-demetylovaného topotekánu.
Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
V moči sa vylúčilo približne 51 % vo forme celkového topotekánu a 3 % sa vylúčili vo forme N-demetylovaného topotekánu.
Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
V moči sa vylúčilo približne 51 % vo forme celkového topotekánu a 3% sa vylúčili vo forme N-demetylovaného topotekánu.
Approximately 51 % was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
V moči sa vylúčilo približne 51% vo forme celkového topotekánu a 3% sa vylúčili vo forme N-demetylovaného topotekánu.
Approximately 51 % was excreted as total topotecan and 3% was excreted as N-desmethyl topotecan in the urine.
Močom sa vylúčilo približne 51 % vo forme celkového topotekánu a 3 % sa vylúčili vo forme N-demetylovaného topotekánu.
Approximately 51% was excreted as total topotecan and 3 % was excreted as N-desmethyl topotecan in the urine.
Močom sa vylúčilo približne 51 % vo forme celkového topotekánu a 3 % sa vylúčili vo forme N-desmetylovaného topotekánu.
Approximately 52% of the patients treated with Revestive experienced adverse reactions (versus 36% of the patients given placebo).
Nežiaduce reakcie sa objavili u približne 52 % pacientov liečených Revestivom (oproti 36 % z pacientov, ktorým sa podávalo placebo).
Approximately 52%, 46%, and 2% of patients were in WHO FC II, III, and IV, respectively.
Približne 52 % bolo vo WHO funkčnej triede II, 46 % bolo vo WHO funkčnej triede III a 2 % pacientov boli vo WHO funkčnej triede IV.
Approximately 58% of patients were male.
Približne 58 % pacientov boli muži.
Approximately 6 % of adults and children 2- to 11-year old are phenotypic poor metabolisers of desloratadine and exhibit a higher exposure (see section 5.2).
Približne 6 % dospelých a detí vo veku 2 až 11 rokov sú fenotypy, ktoré slabo metabolizujú desloratadín a vykazujú vyššiu expozíciu (pozri časť 5.2).
Approximately 6% of patients treated with MIRCERA are expected to experience adverse reactions.
Výskyt nežiaducich reakcií sa očakáva približne u 6 % pacientov liečených MIRCEROU.
Approximately 60 % of an oral dose is absorbed.
Absorbuje sa približne 60 % perorálne podanej dávky.
Approximately 60 % of an oral dose is absorbed.
Absorbuje sa približne 60% perorálne podanej dávky.
Approximately 60% and 15% of the dose are excreted in the urine and faeces, respectively, within 10 days after administration.
Približne 60% dávky sa vylučuje močom a 15% stolicou za 10 dní po podaní.
Approximately 60% of cinacalcet-treated patients achieved a ≥ 30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
U približne 60 % pacientov liečených cinakalcetom sa dosiahla ≥ 30 % redukcia hladín iPTH a tento účinok bol zhodný v celom spektre východiskových hladín iPTH.
Approximately 60% of cinacalcet-treated patients achieved a  30% reduction in iPTH levels, and this effect was consistent across the spectrum of baseline iPTH levels.
U približne 60 % pacientov liečených cinakalcetom sa dosiahla ≥ 30 % redukcia hladín iPTH a tento účinok bol zhodný v celom spektre východiskových hladín iPTH.
Approximately 60% of patients received 3-6 cycles of Arzerra and 32% received 7-12 cycles.
Približne 60 % pacientov podstúpilo 3 - 6 cyklov liečby Arzerrou a 32 % podstúpilo 7 - 12 cyklov.
Approximately 60% of the patients had prior exposure to conventional systemic therapy or phototherapy.
Približne 60 % pacientov bolo predtým liečených konvenčnou systémovou terapiou alebo fototerapiou.
Approximately 60-70% of the dose was recovered in the urine as active substance.
Približne 60 až 70% dávky sa zachytilo v moči vo forme účinnej látky.
Approximately 62 % of palonosetron is bound to plasma proteins.
Približne 62 % palonosetrónu sa viaže na plazmatické bielkoviny.
Approximately 62% of palonosetron is bound to plasma proteins.
Približne 62 % palonosetrónu sa viaže na plazmatické bielkoviny.
Approximately 62% of ranolazine is bound to plasma proteins, and therefore, complete clearance by haemodialysis is unlikely.
Približne 62 % ranolazínu sa viaže na proteíny plazmy, preto úplný klírens po hemodialýze nie je pravdepodobný.
Approximately 65% of an i.v. dose is renally excreted within the first 24 hours.
Približne 65 % i.v. dávky sa vylúči obličkami do prvých 24 hodín.
Approximately 66% of ceftolozane, 56% of tazobactam, and 51% of the M1 metabolite of tazobactam were removed by dialysis.
Približne 66 % ceftolozánu, 56 % tazobaktámu a 51 % metabolitu M1 tazobaktámu sa odstránilo dialýzou.
Approximately 66% of patients were pre-treated with unfractionated heparin.
Približne 66 % pacientov bolo predtým liečených nefrakcionovaným heparínom.
Approximately 66% of the administered dose is eliminated by faeces.
Približne 66% podanej dávky sa vylučuje trusom.
Approximately 68% of the prasugrel dose is excreted in the urine and 27% in the faeces, as inactive metabolites.
Približne 68 % dávky prasugrelu sa vylučuje močom a 27 % stolicou vo forme neaktívnych metabolitov.
Approximately 6–16% of the administered dose was excreted in the urine as unchanged drug.
Približne 6–16% podanej dávky sa vylúčilo močom ako nezmenené liečivo.
Approximately 7% of an oral dose is excreted as unchanged 6– mercaptopurine within 12 hours after administration.
Približne 7 % perorálnej dávky sa vylúči vo forme nezmeneného 6-merkaptopurínu do 12 hodín po podaní.
Approximately 70 % of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment.
Približne 70% pacientov liečených Rebifom môže počas prvých šiestich mesiacov po začiatku liečby očakávať výskyt syndrómu podobnému chrípke typický pre interferón.
Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in subjects with type 2 diabetes mellitus for 12 weeks.
Pri dávke dapagliflozínu 10 mg denne počas 12 týždňov u jedincov s diabetes mellitus 2. typu sa močom vylúčilo približne 70 g glukózy (čo zodpovedá 280 kcal/deň).
Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in subjects with type 2 diabetes mellitus for 12 weeks.
Pri dávke dapagliflozínu 10 mg denne počas 12 týždňov u jedincov s diabetes mellitus typu 2 sa močom vylúčilo približne 70 g glukózy (čo zodpovedá 280 kcal/deň).
Approximately 70 g of glucose was excreted in the urine per day (corresponding to 280 kcal/day) at a dapagliflozin dose of 10 mg/day in subjects with type 2 diabetes mellitus for 12 weeks.
U osôb s diabetes mellitus typu 2 sa pri dávke dapagliflozínu 10 mg/deň počas 12 týždňov vylúčilo močom približne 70 g glukózy denne (čo zodpovedá 280 kcal/deň).
Approximately 70 patients from study EGF114299 who have been randomised to the lapatinib + AI arm with an exposure of approximately 6 months.
Približne 70 pacientov zo štúdie EGF114299, ktorí boli randomizovaní do skupiny s lapatinibom + IA s expozíciou trvajúcou približne 6 mesiacov.
Approximately 70% of patients treated with Rebif can expect to experience the typical interferon flu-like syndrome within the first six months after starting treatment.
Približne 70% pacientov liečených Rebifom môže počas prvých šiestich mesiacov po začiatku liečby očakávať výskyt syndrómu podobnému chrípke typický pre interferón.
Approximately 70% of the orally administered stavudine dose was excreted as an unchanged drug in urine.
Približne 70 % perorálne podanej dávky stavudínu sa vylúčilo v nezmenenej forme v moči.
Approximately 70–80% of pirfenidone is metabolised via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6, and 2E1.
Približne 70–80 % pirfenidónu sa metabolizuje prostredníctvom CYP1A2 s menším prispením iných izoenzýmov CYP vrátane CYP2C9, 2C19, 2D6 a 2E1.
Approximately 71% of the rotigotine dose is excreted in urine and a smaller part of about 23% is excreted in faeces.
Približne 71 % dávky rotigotínu sa vylučuje močom a menšia časť približne 23 % sa vylučuje stolicou.
Approximately 71.4% of the patients on parathyroid hormone reported at least one ADR.
Približne u 71,4  žien zo skupiny s parathormónom sa vyskytol aspoň jeden z ADR.
Approximately 74 % of patients also received single dose oral or intravenous dexamethasone 30 minutes before chemotherapy.
Približne 74 % dostávalo aj jednorazovú perorálnu alebo intravenóznu dávku dexametazónu 30 minút pred chemoterapiou.
Approximately 74% were Caucasian, 4% were Black, 1% were Asian and 19% were of Hispanic origin.
Približne 74 % pacientov bolo kaukazského, 4 % černošského, 1 % ázijského a 19 % hispánskeho pôvodu.
Approximately 75 % of a radioactive dose was recovered during 27 days: 41 % in urine and 34 % in faeces.
Približne 75 % rádioaktívne značenej dávky sa vylúčilo počas 27 dní: 41 % v moči a 34 % v stolici.
Approximately 75 % of the administered dose is eliminated in faeces and the remainder in urine.
Približne 75 % aplikovanej dávky je vylučovaných trusom a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine in dogs.
U psov je približne 75 % aplikovanej dávky je vylučované výkalmi a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
75 % av administrert dose elimineres via fæces, resten via urinen.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % aplikovanej dávky je vylučované výkalmi a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % aplikovanej dávky je vylučovaných trusom a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % aplikovanej dávky sa vylučuje trusom a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % podanej dávky sa eliminuje stolicou a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % podanej dávky sa vylúči fekáliami a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % podanej dávky sa vylúči stolicou a zvyšok močom.
Approximately 75 % of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75% podanej dávky sa vylúči fekáliami a zvyšok močom.
Approximately 75 % of the administered dose of meloxicam is eliminated via faeces and the remainder via urine.
Približne 75 % podanej dávky meloxikamu je vylučovaných fekáliami a zvyšok močom.
Approximately 75% of patients had no prior pharmacological treatment for incontinence.
Približne 75 % pacientov neabsolvovalo predchádzajúcu farmakologickú liečbu inkontinencie.
Approximately 75% of the administered [14C] nateglinide is recovered in the urine within six hours post-dose.
Približne 75% podaného [14C] nateglinidu sa nájde v moči počas 6 hodín po podaní.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
75 % av administrert dose elimineres via fæces, resten via urinen.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % aplikovanej dávky je vylučovaných trusom a zvyšok močom.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75 % aplikovanej dávky sa vylučuje trusom a zvyšok močom.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75% aplikovanej dávky je vylučované výkalmi a zvyšok močom.
Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.
Približne 75% podanej dávky sa vylúči fekáliami a zvyšok močom.
Approximately 75% of the patients with metastatic colorectal cancer screened for clinical studies had an EGFR-expressing tumour and were therefore considered eligible for cetuximab treatment.
Približne 75 % pacientov s metastatickým kolorektálnym karcinómom, ktorí boli v rámci klinických štúdií vyšetrení, malo nádor s expresiou EGFR, a preto sa považovali za vhodných kandidátov na liečbu cetuximabom.
Approximately 77% of patients had recurrent ischaemia, approximately 70% had dynamic ECG changes or elevated cardiac biomarkers, approximately 28% had diabetes and approximately 99% of patients underwent angiography within 72 hours.
Približne 77 % pacientov malo rekurentnú ischémiu, približne 70 % malo dynamické zmeny na EKG alebo zvýšené srdcové biomarkery, približne 28 % malo diabetes a približne 99 % sa podrobilo angiografii do 72 hodín.
Approximately 79 % of sitagliptin is excreted unchanged in the urine.
Približne 79 % sitagliptínu sa vylúči nezmenených v moči.
Approximately 8% of patients had a severe ADR (common toxicity criteria, (CTC) grade 3 or 4).
Približne u 8% pacientov sa objavila ťažká nežiaduca reakcia (common toxicity criteria, (CTC) stupeň 3 alebo 4).
Approximately 80 % of the dose is excreted in urine and faeces within 4 days.
Približne 80 % dávky sa vylúči močom a stolicou počas 4 dní.
Approximately 80 % of the dose is excreted in urine and feces within 4 days.
Približne 80 % dávky sa vylúči močom a stolicou počas 4 dní.
Approximately 80 % of the intravenously administered dose of sufentanil is excreted within 24 hours.
Približne 80 % intravenózne podanej dávky sufentanilu sa vylúči v priebehu 24 hodín.
Approximately 80 - 100 % of the medicinal product is excreted by the kidneys within 24 hours as the conjugated product, phenylacetylglutamine.
Okolo 80 – 100 % lieku sa vylúči obličkami do 24 hodín ako konjugovaný produkt, fenylacetylglutamín.